echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Inventory of the top ten hot topics in the pharmaceutical industry in 2019

    Inventory of the top ten hot topics in the pharmaceutical industry in 2019

    • Last Update: 2019-12-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2019 is a severe test for Chinese pharmaceutical enterprises and practitioners Under the multiple influences of 4 + 7, medical insurance fee control, tax verification, licensed pharmacists' license fixing, DRGs payment and other policies, the high gross profit of the pharmaceutical industry is running off, and the shuffling is intensifying A number of enterprises are cancelled, laid off, and shut down, so the transformation and upgrading are imminent How to define the pharmaceutical industry in 2019, and what are its key words? Looking back on the past year's events will eventually bring inspiration to people and converge into the direction of progress 1 The release of 4 + 7 power counts the major events of medicine in 2019, and it is incomplete without "4 + 7 volume purchase" In January 2019, the state issued a pilot program for centralized purchase and use of drugs, with clear guiding ideology, objectives and operation methods By September, the pilot range of 4 + 7 volume procurement was expanded Subsequently, many provinces issued relevant supporting documents Shandong, Jiangsu, Jiangxi, Anhui, Liaoning and other places even introduced products and consumables beyond 4 + 7 into the volume purchase, and the local version price war was staged The power of 4 + 7 volume purchase is directly displayed in "soul bargaining" This is not only an important measure for the country to reduce drug prices and promote people's livelihood, but also a powerful driving force for pharmaceutical enterprises to turn to high-quality development In addition, under the combined effect of multiple procurement modes such as Sanming alliance, Shenzhen GPO, Guangzhou GPO, Shanghai GPO and Guangxi GPO, drug price reduction is still the main direction 2 Since the downsizing of pharmaceutical enterprises this year, many pharmaceutical enterprises have disbanded their sales teams, which has nothing to do with "4 + 7" On the one hand, the selected varieties can enter the national market without public relations The original salesperson either transforms, transfers to other product lines or is laid off The original market share of the unsuccessful varieties will be squeezed by the winning varieties, or the revenue will decline, and the cost of supporting marketing will be reduced In this case, the sales team will also face the dissolution On the other hand, the volume purchase will give the generic drugs passing the consistency evaluation a fair competition opportunity with the original research drugs The advantages of foreign enterprises will be reduced, and some businesses will be removed or adjusted to meet the New changes to the market 3 In 2019, Kangmei pharmaceutical industry was exposed to financial fraud, which caused market consternation and attracted high attention of regulatory authorities In June, the Ministry of Finance issued a notice to check the financial problems and cost of 77 pharmaceutical enterprises It extended the inspection of related party enterprises and related sales, agency, advertising and consulting institutions, and extended to medical institutions if necessary In addition, listed pharmaceutical companies received inquiries and regulatory letters from regulatory authorities due to the excessive growth of sales expenses, even exceeding the growth of revenue, and asked to explain the rationality of the growth of sales expenses For a while, the pharmaceutical industry shuddered How to comply with the sales regulations has become a serious problem facing the pharmaceutical industry The industry believes that by checking the storm, to some extent, it will deter those pharmaceutical enterprises that develop through financial fraud and high kickback, and crack down on corruption in the pharmaceutical field, which is conducive to the high-quality development of the pharmaceutical industry 4 The focus of "blocking" medical e-commerce in 2019 may not be the double 11 or double 12 Since this year, a number of pharmaceutical companies have issued documents to "block" pharmaceutical e-commerce, requiring downstream distributors to stop supplying to the network platform because of "disorderly price of e-commerce" In the view of the industry, the inherent price transparency and low price drainage of pharmaceutical e-commerce have impacted the original price system of pharmaceutical enterprises, even the sales system The emergence of medical e-commerce has opened up a new path for the sale of medicine and brought convenience to people's purchase of medicine Next, the game among pharmaceutical enterprises, distributors and medical e-commerce will not stop, but there is room for cooperation 5, "Internet plus" continues to affect 2019, and the state explicitly incorporates Internet health care into the scope of medical insurance payment The Internet plus medical service has been developing rapidly, and many prescription transfer platforms are available In the field of drug circulation, as a national third-party service platform in the pharmaceutical industry, the "001 first business electronic data exchange platform", "001 first business electronic data exchange third terminal version" applet jointly developed by Shenzhen Henghe Internet and China Mobile CA center and the "electronic inspection report receiving and sending platform" are helping the pharmaceutical industry to innovate and upgrade Among them, single drugstores, clinics and health rooms can receive and send the first sale electronic data free of charge through the "001 first sale electronic data exchange third terminal version" applet 6 It may be a watershed for licensed pharmacists to check their licenses in 2019 After CCTV 3.15 exposed the phenomenon of licensed pharmacists hanging licenses, the State Food and drug administration carried out special actions to strictly inspect licensed pharmacists in retail enterprises Subsequently, a number of licensed pharmacists were cleared and pharmacies were punished Just when people thought that licensed pharmacists would be more valuable, the policy announced that licensed pharmacists could practice more Coupled with the implementation of unified registration of licensed pharmacists in drug chain enterprises, the head of chain stores can no longer be a licensed pharmacist, so the shortage of licensed pharmacists has been alleviated, but its position is a bit awkward 7 On December 1, the new law came into force in the field of medicine, which means that the vaccine administration law and the newly revised Drug Administration Law were officially implemented, which will further ensure the quality of drugs, protect the safety and legitimate rights and interests of the public, and protect and promote public health 8 The newly revised Drug Administration Law on the cancellation of GMP and GSP certification is clear, no longer accepts GMP and GSP certification applications, and no longer issues GMP and GSP certificates Subsequently, the provincial drug administration followed up Industry insiders said that deregulation does not mean deregulation, but more stringent In the past, GMP and GSP regulations still need to be done In addition, the previous five-year test is now replaced with a test at any time, which means that pharmaceutical enterprises should always be legally compliant with production and operation, and nothing can be done temporarily 9 With the implementation of the newly revised "Drug Administration Law", the system of drug listing license holders has moved to the whole country There is no doubt that this national initiative is to optimize resources and innovate The independence of marketing license and production license is conducive to drug R & D and innovation, to improving regulatory efficiency, and to clarifying the legal responsibilities of each subject 10 After the retail drugstore is connected to the "4 + 7" centralized purchase, the hospital medicine appears depression If the drugstore wants to retain customers, the drug price may also need to be lowered However, due to different purchase channels, drug prices in drugstores are difficult to match those in hospitals With the collection of Medicare drugs in pharmacies in Shandong, Zhejiang, Shanghai, Guangdong and other provinces, the drug prices in pharmacies and hospitals are likely to be unified However, industry insiders said that it is difficult to smooth the price difference between drugs inside and outside the hospital Even if drugs are purchased on a unified purchasing platform, the profit of drugstores still depends on the price difference between purchase and sales, while public hospitals rely on medical services Generally speaking, the state's attitude towards the pharmaceutical industry is to accelerate the listing of innovative drugs and the price reduction of generic drugs On the one hand, support the research and development of domestic pharmaceutical enterprises; on the other hand, zero tariff for anti-cancer drugs, further reduce the price of generic drugs, while using the 4 + 7 huge market to reduce the price On the train to 2020, transformation pains and embracing innovation will be the necessary stage for China's pharmaceutical industry to move towards the future and the world.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.